A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight

Part 1: To investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 3034701 in Japanese male and female participants with body mass index (BMI) ≥27.0 kg/m² or more following subcutaneous administration of multiple rising doses over 16 weeks. Part 2: To investigate safety, tolerability, and PK of BI 3034701 in Japanese male and female healthy participants with BMI ≥23.0 to \<27.0 kg/m² following subcutaneous administration of multiple rising doses over 7 weeks.

NCT Number	NCT07693231
Lead Sponsor	Boehringer Ingelheim
Conditions	Healthy, Obesity
Enrollment	48 participants
Start Date	2026-07-21
Primary Completion	2026-12-22 (estimated)
Study Completion	2027-01-05 (estimated)
Updated on ClinicalTrials.gov	2026-07-24